ERBB2 and neoplasm: All mice treated with HER2-specific CART had survival benefit without tumor progression (Fig. 7E) compared with no treatment (P < 0.01, log-rank test, Holm–Sidak method) or sham treatment with NT T cells (P < 0.05, log-rank test, Holm–Sidak method).